Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.

NCT07072728 is registered in ClinicalTrials.gov with Psyence Australia Pty Ltd as lead sponsor.

NCT NCT07072728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07072728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.
Lead sponsor
Psyence Australia Pty Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2025
Completion date
July 30, 2027
Enrollment
87 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adjustment disorder, adjustment disorder with anxious mood, cancer, cancer cachexia, cancer melanoma skin, cancer of endometrium, cancer of kidney, cancer of prostate, cancer of stomach, cancer of the breast, cancer pancreas